clinical trials
Recovery Mode
AI-designed TEAD inhibitor shows tumor shrinkage
Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control in early trials.
Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control in early trials.